Letter from the president

As Scripps Research marks the end of its first century and begins the next, one fact remains constant: science never stands still.

Since its founding in 1924, Scripps Research has continually innovated, keeping the institute at the vanguard of science and driving outsized impact on human health. In 2024, our labs continued to make critical advances in their fields and many of our faculty were duly recognized for their breakthroughs. The institute set a record this year with nine exceptional scientists appointed to the faculty, further strengthening our interdisciplinary capabilities.

The Calibr-Skaggs Institute for Innovative Medicines, our drug discovery division, continued its unprecedented productivity in the clinic, and The Wall Street Journal featured our innovative therapies to repair and reverse the effects of aging. Also profiled in the media, scientists at the Scripps Research Translational Institute led studies exploring everything from the links between sleep and dementia to the use of artificial intelligence to diagnose heart attacks.

As our need for laboratory space grows, we inaugurated the Chi-Huey Wong Laboratories for Biomedical Research, a state-of-the-art, 83,000-square-foot facility that will foster collaborations across chemical and life sciences. The Skaggs Graduate School of Chemical and Biological Sciences likewise had a banner year, graduating our largest class to date and receiving the most applications in the program’s history.

These and other accomplishments featured in this issue of Scripps Research Magazine speak to remarkable momentum propelling us into our second century. As we enter our next chapter, we are committed to pushing the boundaries of knowledge, to accelerating the development of innovative medicines, and to addressing the significant health challenges facing humanity in the 21st century.

It’s impossible to predict how Scripps Research will look in 2124, but it’s certain that we will continue to redefine what’s possible.